Amphista Therapeutics develops next-generation targeted protein degradation (TPD) approaches using its proprietary Eclipsys™ platform and bifunctional molecules. Its approach leverages a wider range of the body’s innate protein-degrading mechanisms rather than the narrow set of ubiquitin E3 ligase-based mechanisms used by many first-generation TPD companies. This differentiation aims to overcome limitations of current TPD methods and enable targeting of indications that are largely inaccessible to traditional TPD, including central nervous system (CNS) diseases. The company plans to accelerate pre-clinical development with a particular focus on neurodegeneration and dementia, alongside work in severe diseases such as cancer. Amphista was founded by Advent Life Sciences as a spin-out of Professor Alessio Ciulli’s labs at the University of Dundee and is based in Cambridge, UK. The company has raised over $60M to date and is funded by investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, BioMotiv and Eli Lilly & Company. Amphista Therapeutics is a biopharmaceutical company developing next-generation targeted protein degradation (TPD) therapeutics. Its pipeline centers on potent, selective bifunctional molecules called 'Amphistas' designed to selectively degrade disease-causing proteins. The company is focused on challenging diseases including cancer and aims to harness the body’s natural processes to efficiently remove pathogenic proteins. Amphista intends to advance its Amphistas to the clinic and extend its proprietary TPD platform. Led by CEO Nicola Thompson, the company was founded by Advent Life Sciences as a spin-out of Professor Alessio Ciulli’s labs at the University of Dundee and is based in Glasgow, Scotland, UK. Amphista Therapeutics is a Glasgow, Scotland-based biopharmaceutical company led by CEO Nicola Thompson and founded on the work of Professor Alessio Ciulli at the University of Dundee. The company develops targeted protein degradation (TPD) small molecules that instruct cells to degrade disease-causing proteins rather than inhibit them. Its platform is independent of traditional E3 ubiquitin ligases, potentially expanding the available target scope and addressing recently identified PROTAC resistance mechanisms. Amphista is focused on creating cancer therapeutics and advancing an oncology pipeline. The company closed a $7.5M Series A and intends to use the funds to progress its oncology programs toward the clinic. In conjunction with the financing, Satish Jindal, CEO of BioMotiv, joined Amphista’s board as Chairman.

Total raised

$60M

Funding rounds

3

Latest round

Series B

Latest activity

Mar 2021